User: Guest  Login
Less Searchfields
Simple search
Title:

Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.

Document type:
Journal Article
Author(s):
Brueckl, Wolfgang M; Reck, Martin; Rittmeyer, Achim; Kollmeier, Jens; Wesseler, Claas; Wiest, Gunther H; Christopoulos, Petros; Tufman, Amanda; Hoffknecht, Petra; Ulm, Bernhard; Reich, Fabian; Ficker, Joachim H; Laack, Eckart
Abstract:
Background: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was to evaluate the efficacy of ramucirumab plus docetaxel (R + D) as third-line treatment after failure of a first-line platinum-based chemotherapy and a second-line ICI treatment in patients with non-small-cell lung cancer (NSCLC) stage IV. Methods: Retrospec...     »
Journal title abbreviation:
Clin Med Insights Oncol
Year:
2020
Journal volume:
14
Fulltext / DOI:
doi:10.1177/1179554920951358
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/32884390
TUM Institution:
Klinik für Anästhesiologie (DHM)
 BibTeX